Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

Jenny J Wei¹, Lisa R Kallenbach², Maryl Kreider³, Thomas H Leung^{1

4}, Misha Rosenbach¹

Affiliations

¹ University of Pennsylvania Perelman School of Medicine, Department of Dermatology, Philadelphia, Pennsylvania.
² University of Pennsylvania Presbyterian Medical Center, Department of Hematology Oncology, Philadelphia, Pennsylvania.
³ University of Pennsylvania, Department of Pulmonary, Allergy & Critical Care, Philadelphia, Pennsylvania.
⁴ Corporal Michael Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.

PMID: 31008168
PMCID: PMC6453827
DOI: 10.1016/j.jdcr.2019.02.006

Case Reports

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

Jenny J Wei et al. JAAD Case Rep. 2019.

. 2019 Apr 5;5(4):360-361.

doi: 10.1016/j.jdcr.2019.02.006. eCollection 2019 Apr.

Authors

Jenny J Wei¹, Lisa R Kallenbach², Maryl Kreider³, Thomas H Leung^{1

4}, Misha Rosenbach¹

Affiliations

¹ University of Pennsylvania Perelman School of Medicine, Department of Dermatology, Philadelphia, Pennsylvania.
² University of Pennsylvania Presbyterian Medical Center, Department of Hematology Oncology, Philadelphia, Pennsylvania.
³ University of Pennsylvania, Department of Pulmonary, Allergy & Critical Care, Philadelphia, Pennsylvania.
⁴ Corporal Michael Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.

PMID: 31008168
PMCID: PMC6453827
DOI: 10.1016/j.jdcr.2019.02.006

No abstract available

Keywords: JAK inhibitor; JAK, Janus kinase; JAK-STAT, Janus kinase–signal transducer and activator of transcription; Janus kinase inhibitor; Janus kinase–signal transducer and activator of transcription; PV, polycythemia vera; ruxolitinib; sarcoidosis.

PubMed Disclaimer

Figures

**Fig 1**
A, Granulomatous dermatitis extending from the mid dermis to the subcutaneous tissue, with focal involvement. B, Granulomas are relatively pauci-inflammatory, overall small to medium in size, and well formed. Focally intermixed lymphocytes are seen. There is also an admixture of lymphocytes, rare neutrophils, and plasma cells within the interstitium. (A and B, Hematoxylin-eosin stain; original magnifications: A, ×4; B, ×10.)

See this image and copyright information in PMC

Cited by

Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Damsky W, et al. J Am Acad Dermatol. 2020 Mar;82(3):612-621. doi: 10.1016/j.jaad.2019.05.098. Epub 2019 Jun 8. J Am Acad Dermatol. 2020. PMID: 31185230 Free PMC article.
Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis.
Talty R, Damsky W, King B. Talty R, et al. JAAD Case Rep. 2021 Aug 20;16:62-64. doi: 10.1016/j.jdcr.2021.08.012. eCollection 2021 Oct. JAAD Case Rep. 2021. PMID: 34522749 Free PMC article. No abstract available.
Recent Clinical Studies on the Effects of Tumor Necrosis Factor-Alpha (TNF-α) and Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Antibody Therapies in Refractory Cutaneous Sarcoidosis: A Systematic Review.
Toriola SL, Satnarine T, Zohara Z, Adelekun A, Seffah KD, Salib K, Dardari L, Taha M, Dahat P, Penumetcha SS. Toriola SL, et al. Cureus. 2023 Sep 8;15(9):e44901. doi: 10.7759/cureus.44901. eCollection 2023 Sep. Cureus. 2023. PMID: 37818515 Free PMC article. Review.
Current Insights in Genetics of Sarcoidosis: Functional and Clinical Impacts.
Calender A, Weichhart T, Valeyre D, Pacheco Y. Calender A, et al. J Clin Med. 2020 Aug 13;9(8):2633. doi: 10.3390/jcm9082633. J Clin Med. 2020. PMID: 32823753 Free PMC article. Review.
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.
Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Damsky W, et al. Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x. Nat Commun. 2022. PMID: 35668129 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Valeyre D., Prasse A., Nunes H., Uzunhan Y., Brillet P.Y., Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155–1167. - PubMed
1. James C., Ugo V., Le Couédic J.P. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. - PubMed
1. Lower E.E., Smith J.T., Martelo 0.J., Baughman R.P. The anemia of sarcoidosis. Sarcoidosis. 1988;5:51–55. - PubMed
1. Damsky W., King B.A. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. - PMC - PubMed
1. Zhou T., Casanova N., Pouladi N. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017;7(1):2–10. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

Affiliations

Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera

Authors

Affiliations

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources